3 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Qurient Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Q702, Pembrolizumab - Esophageal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Qurient Co., Ltd. | 120 | 2023-01-12 | 2026-02-24 |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Q901, KEYTRUDA® (pembrolizumab) - Advanced Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Qurient Co., Ltd. | 130 | 2022-08-30 | 2025-08-17 |
| A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Telacebec, COVID-19 Standard of care - COVID-19 Virus Infection | Phase 2 | Terminated | Qurient Co., Ltd. | 1 | 2021-07-29 | 2022-03-02 |
| A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) Telacebec (Q203), Rifafour e-275 - Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB | Phase 2 | Completed | Qurient Co., Ltd. | 60 | 2018-07-23 | 2019-09-10 |
| Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients Q301 Cream, Vehicle - Atopic Dermatitis | Phase 2 | Completed | Qurient Co., Ltd. | 258 | 2018-06-21 | 2020-04-24 |
| Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients Q301 Cream, Placebo - Moderate to Severe Atopic Dermatitis | Phase 2 | Completed | Qurient Co., Ltd. | 57 | 2015-04-01 | 2016-12-06 |
COVID-19 (1) · Dermatitis, Atopic (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)
pembrolizumab (2) · telacebec (2)
United States (4) · South Africa (2) · South Korea (2)